File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cancers13225700
- Scopus: eid_2-s2.0-85118878537
- PMID: 34830854
- WOS: WOS:000727039800001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development
Title | The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development |
---|---|
Authors | |
Keywords | Hepatocellular carcinoma (HCC) Post-translational modification SUMOylation Cancer metastasis Cancer drug resistance |
Issue Date | 2021 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/ |
Citation | Cancers, 2021, v. 13 n. 22, article no. 5700 How to Cite? |
Abstract | Small ubiquitin-like modifier (SUMO) is a highly conserved post-translational modification protein, mainly found in eukaryotes. They are widely expressed in different tissues, including the liver. As an essential post-translational modification, SUMOylation is involved in many necessary regulations in cells. It plays a vital role in DNA repair, transcription regulation, protein stability and cell cycle progression. Increasing shreds of evidence show that SUMOylation is closely related to Hepatocellular carcinoma (HCC). The high expression of SUMOs in the inflammatory hepatic tissue may lead to the carcinogenesis of HCC. At the same time, SUMOs will upregulate the proliferation and survival of HCC, migration, invasion and metastasis of HCC, tumour microenvironment as well as drug resistance. This study reviewed the role of SUMOylation in liver cancer. In addition, it also discussed natural compounds that modulate SUMO and target SUMO drugs in clinical trials. Considering the critical role of SUMO protein in the occurrence of HCC, the drug regulation of SUMOylation may become a potential target for treatment, prognostic monitoring and adjuvant chemotherapy of HCC. |
Persistent Identifier | http://hdl.handle.net/10722/309056 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.391 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuan, H | - |
dc.contributor.author | Lu, Y | - |
dc.contributor.author | Chan, YT | - |
dc.contributor.author | Zhang, C | - |
dc.contributor.author | Wang, N | - |
dc.contributor.author | Feng, Y | - |
dc.date.accessioned | 2021-12-14T01:39:59Z | - |
dc.date.available | 2021-12-14T01:39:59Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Cancers, 2021, v. 13 n. 22, article no. 5700 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/10722/309056 | - |
dc.description.abstract | Small ubiquitin-like modifier (SUMO) is a highly conserved post-translational modification protein, mainly found in eukaryotes. They are widely expressed in different tissues, including the liver. As an essential post-translational modification, SUMOylation is involved in many necessary regulations in cells. It plays a vital role in DNA repair, transcription regulation, protein stability and cell cycle progression. Increasing shreds of evidence show that SUMOylation is closely related to Hepatocellular carcinoma (HCC). The high expression of SUMOs in the inflammatory hepatic tissue may lead to the carcinogenesis of HCC. At the same time, SUMOs will upregulate the proliferation and survival of HCC, migration, invasion and metastasis of HCC, tumour microenvironment as well as drug resistance. This study reviewed the role of SUMOylation in liver cancer. In addition, it also discussed natural compounds that modulate SUMO and target SUMO drugs in clinical trials. Considering the critical role of SUMO protein in the occurrence of HCC, the drug regulation of SUMOylation may become a potential target for treatment, prognostic monitoring and adjuvant chemotherapy of HCC. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/ | - |
dc.relation.ispartof | Cancers | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Hepatocellular carcinoma (HCC) | - |
dc.subject | Post-translational modification | - |
dc.subject | SUMOylation | - |
dc.subject | Cancer metastasis | - |
dc.subject | Cancer drug resistance | - |
dc.title | The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development | - |
dc.type | Article | - |
dc.identifier.email | Yuan, H: hcyuan@hku.hk | - |
dc.identifier.email | Wang, N: ckwang@hku.hk | - |
dc.identifier.email | Feng, Y: yfeng@hku.hk | - |
dc.identifier.authority | Wang, N=rp02075 | - |
dc.identifier.authority | Feng, Y=rp00466 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/cancers13225700 | - |
dc.identifier.pmid | 34830854 | - |
dc.identifier.pmcid | PMC8616375 | - |
dc.identifier.scopus | eid_2-s2.0-85118878537 | - |
dc.identifier.hkuros | 330744 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 22 | - |
dc.identifier.spage | article no. 5700 | - |
dc.identifier.epage | article no. 5700 | - |
dc.identifier.isi | WOS:000727039800001 | - |
dc.publisher.place | Switzerland | - |